ResMed has still an uptrend and is going toward its highest level.

The company’s fundamentals are still strong. Sales are up 9.3% for one year. Analysts from Thomson Reuters consensus have revised largely upward their EPS estimates. The last EPS was at USD 1.71.

From a technical viewpoint, the security is trading in a bullish trend in the short and the long term. Increasing moving averages let think there will be no reversal in the coming trading sessions. This growth should help to reach soon the USD 44.5 level.

According to these elements, investors can take a long position above USD 42.5 on the current level to target USD 44.5. A stop loss order will be fixed under USD 42.1 to protect the capital from a reversal.